Program

Thursday, June 14, 2012

8:15 Registration	
8:45 President	Welcome
8:50 Enrico Mihich	Introduction
9:00 David Livingston	Focus & Goals
8:45 Jeffrey Engelman	– Keynote Ada

 Keynote Address: Challenges in overcoming resistance to kinase inhibitors

Session I, Genetics of Resistance I

Chair/Moderator: Lewis Chodosh

10:00 Lewis Chodosh 10:25 Discussion 10:45 Coffee break	 Mechanisms of tumor dormancy and recurrence
11:05 Elaine Mardis 11:30 Discussion	 Genomic exploration of therapy resistance
11:50 Thomas O'Hare 12:15 Discussion	 Compounding the prob- lem of clinical resistance to TKIs in CML
12:35 Levi Garraway 13:00 Discussion	- Defining the spectrum of resistance to targeted anti-
13:20 Lunch	cancer agents

Session II, Clinical Advances in Overcoming Resistance

Chair/Moderator: Jose Baselga

The Pezcoller Symposia

	Jose Baselga Discussion	- Reverting endocrine resistance by targeting the mTOR pathway: A new paradigm in the therapy of breast cancer
	Jeff Sosman Discussion	 Clinical approaches to BRAF inhibitor resistance in melanoma
16:25	Johan de Bono Discussion Adjourn	- Improving outcome from prostate cancer

Program

Friday, June 15, 2012

Session III, Resistance through Perturbed Signaling

Chair/Moderator: Richard Marais

	Richard Marais Discussion	 BRAF and RAS signaling in cancer; translating basic under- standing into clinical benefit
9:15	Alberto Bardelli	- Mechanisms of resistance to
9:40	Discussion	EGFR targeted therapies in colorectal cancer
10:00	Coffee break	
10:20	Neal Rosen	- Adaptive resistance to onco-
10:45	Discussion	protein inhibition
11:05	Rafaella Sordella	- Intrinsic and extrinsic mecha-
11:30	Discussion	nisms of erlotinib resistance in NSCLC

11:50 Poster Session & Lunch

Session IV, Genetics of Resistance II

Chair/Moderator: William Sellers

20:00 Symposium Dinner

	William Sellers	- Approaches to the discovery
14:25	Discussion	and treatment of therapeutic resistance
14:45	Jos Jonkers	- Studying therapy response
15:10	Discussion	and resistance in mouse models
		BRCA-associated breast cancer
15:30	Roman Thomas	 Lung cancer genomics
15:55	Discussion	
16:25	Giulio Superti-Furga	- Effectors and targets of anti-
16:50	Discussion	cancer agents
17:10	Silvia Buonamici	- Identifying the mechanisms
17:35	Discussion	of resistance to smoothened in-
		hibitors
17:50	Adjourn	

Program

Saturday, June 16, 2012

12:30 Lunch & Adjourn

The Pezcoller Symposia

8:00 Best Posters' Oral Presentations

Session V, Role of the Tumor Microenvironment in Resistance Chair/Moderator: David Tuveson

0.00	David Tuveson	- The pancreatic tumor stroma
9:25	Discussion	influences therapeutic response
9:45	Ben Stanger	- The dynamics of primary tu-
10:10	Discussion	mor spread in pancreatic cancer
10:30	James Allison	- Immune checkpoint blockade:
10:50	Discussion	New insights and opportunities
11:20	Todd Golub	- Systematic approaches to
11:45	Discussion	discovering microenvironment-
		mediated drug resistance
12:05	David Livingston	- Concluding Remarks

Invited Participants

- James Allison Memorial Sloan Kettering Cancer Ctr, New York, NY

Alberto Bardelli
 Inst for Cancer Res & Treatment, Candiolo, Torino, I

Jose Baselga
 Massachusetts General Hospital, Boston, MA
 Vall D'Hebron Inst of Oncology, Barcelona, E

- Silvia Buonamici H3 Biomedicine, Inc., Cambridge, MA

- Lewis Chodosh Univ of Pennsylvania, Philadelphia, PA

- Johann de Bono Institute of Cancer Research, London, UK

Jeffrey Engelman
 Massachusetts General Hospital, Charlestown, MA

- Levi Garraway Dana Farber Cancer Inst, Boston, MA

- Todd Golub Broad Inst at MIT, Cambridge, MA

Jos Jonkers
 Netherlands Cancer Inst, Amsterdam, NL

- **David Livingston**Dana Farber Cancer Inst, Boston, MA

- Richard Marais
The Inst of Cancer Research, London, UK

The Pezcoller Symposia

6

The Pezcoller Symposia

Invited Participants

- Elaine Mardis
 The Genome Inst at Washington Univ., St. Louis, MO
- Enrico Mihich
 Dana Farber Cancer Inst, Boston, MA
- Thomas O'Hare Univ of Utah School of Medicine, Salt Lake City, UT
- Neal Rosen Memorial Sloan Kettering Cancer Ctr, New York, NY
- William Sellers
 Novartis Inst for Biomedical Res, Cambridge, MA
- Rafaella Sordella Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- **Jeffrey Sosman** Vanderbilt Univ, Nashville, TN
- **Ben Stanger** University of Pennsylvania, Philadelphia, PA
- Giulio Superti-Furga CeMM Res Ctr Molecular Medicine. Vienna. A
- Roman Thomas University Hospital Cologne, Cologne, D
- **David Tuveson**Cambridge Research Inst, Cambridge, UK

The Pezcoller Foundation

The Pezcoller Foundation is a non-profit organisation created in 1980 by Prof. Alessio Pezcoller (1896 - 1993), Chief Surgeon at Santa Chiara Hospital of Trento, Italy. The goal of the Foundation is to promote biomedical research.

Activities:

- PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR CANCER RESEARCH – 75.000 Euro: this prize is presented, every year, to a scientist who has made a major scientific discovery in the field of cancer.
- PEZCOLLER FOUNDATION-ECCO RECOGNITION FOR CONTRIBUTION TO ONCOLOGY – 30.000 Euro: this prize is presented, every two years to a single individual (scientist, clinician, nurse. etc.) for his/her professional life dedication to the improvement of cancer treatment, care and research.
- THE PEZCOLLER SYMPOSIA: a series of annual symposia promoting interactions among scientists working at the cutting edge of basic oncological sciences.
- PEZCOLLER SEMINARS: a series of educational meetings for medical doctors.
- PEZCOLLER FOUNDATION FELLOWSHIPS: for professional updating in oncology.
- PEZCOLLER FOUNDATION GRANTS: for oncological research programs.
- THE PEZCOLLER FOUNDATION JOURNAL: this periodical is published in order to provide a direct link, at six month interval, between the Pezcoller Foundation and the international medical and scientific community.
- PEZCOLLER-EACR AWARD: celebrating academic excellence and achievements of young researchers in the field of cancer. This prestigious award and lecture is presented at the Biennal EACR Congress. The award includes 10,000 Euro plus expenses covering travel, accommodation and congress fees.

This Symposium is supported by

- Fondazione Cassa di Risparmio di Trento e Rovereto
- Provincia Autonoma di Trento
- Comune di Trento
- Comune di Rovereto

8

The Pezcoller Symposia

24th Pazcollar Symposium

MOLECULAR BASIS FOR RESISTANCE TO TARGETED AGENTS

> Trento, Italy, June 14-16, 2012

Fondazione PEZCOLLER
Via Dordi, 8
38122 TRENTO - Italy
Tel. 0039 - 0461 - 980250
Fax 0039 - 0461 - 980350
E-mail: pezcoller@pezcollerit
Web: www.nezcollerit

The Pezcoller Foundation Symposia

24th Pezcoller Symposium

MOLECULAR BASIS FOR RESISTANCE TO TARGETED AGENTS

Trento, Italy, June 14-16, 2012 Conference Hall Fondazione Cassa di Risparmio di Trento e Rovereto, via Calepina 1 – 38122 Trento

Co-Chairmen and Program Committee Richard Marais, William Sellers, David Livingston and Enrico Mihich

The topic will be *Molecular Basis for Resistance to Targeted Agents*, and the focus of the meeting will be the mechanisms of resistance to new tumor target therapies.

The meeting is being co-organized by Richard Marais (Institute of Cancer Research, London, UK), William Sellers (Novartis Institute for Biomedical Research, Cambridge, MA), David Livingston (Dana Farber Cancer Institute, Boston, MA) and with the collaboration of Enrico Mihich (Dana Farber Cancer Institute, Boston, MA).

The Symposium will be opened by the keynote address of Jeffrey Engelman (MGH, Charlestown, MA).

There will be 22 speakers divided in five sessions: genetics of resistance I and II; clinical advance in overcoming resistance; resistance through perturbed signalling; role of the tumor microenvironment in resistance.

Speakers give approximately 25 minute talks followed by a similar amount of time for discussion. These meetings have always provided a major opportunity for scientific interaction among participants.

General Information

Travel and local arrangements

Fondazione Alessio Pezcoller Via Dordi, 8 - 38122 Trento (Italy)

 Phone
 0039-0461-980250

 Fax
 0039-0461-980350

 E-mail:
 pezcoller@pezcoller.it

 Web:
 www.pezcoller.it



Scientific reference

David Livingston - Dana Farber Cancer Institute david livingston@dfci.harvard.edu
Tel 617-632-3074 Fax 617-632-4381, or
Enrico Mihich - Dana Farber Cancer Institute enrico mihich@dfci.harvard.edu

Location

The Conference will be held at Conference Hall of Fondazione Cassa di Risparmio di Trento e Rovereto, Via Calepina, 1 - 38122, Trento (Italy)

Attendance at the meeting will be limited to a maximum of 100 participants.

Registration Fee

€ 200 (as a contribution to Symposium's expenses) payable at the time of acceptance, directly to the symposium venue. The registration fee includes: participation to the symposium, congress kit, working lunches, coffee breaks, symposium dinner.

Posters

A limited number of poster presentations will be accepted on a competitive basis. **Pezcoller-Begnudelli Fellowships will be given to the 3 best posters**. To submit a poster send a one-page abstract to Dr. Mihich (by 18 May, 2012).

E-mail: enrico_mihich@dfci.harvard.edu

Hotel accommodations (bed and breakfast - target prices)

H. Venezia - P.za Duomo € 72 (only double room) Tel. 39 0461 234559 AlberMonaco - Via Torre d'Augusto € 63/95 (single/double room) Tel. 39 0461 983060

 $\begin{array}{ll} \textit{H. Accademia - Via Colico} & \textit{€ 68/90 (single/double room)} & \textit{Tel. 39 0461 233600} \\ \textit{H. America - Via Torre Verde} & \textit{€ 68/108 (single/double room)} & \textit{Tel. 39 0461 983010} \\ \end{array}$

H. Buonconsiglio - via Romagnosi € 78/98 (single/double room) Tel. 39 0461 272888 H. Trento - Via Alfieri € 98/108 (single/double room) Tel. 39 0461 271000

All hotels are at walking distance from the conference hall.

Registration Form

MOLECULAR BASIS FOR RESISTANCE TO TARGETED AGENTS

Trento - Italy June 14-16, 2012 Last Name: First Name: Affiliation: Address: Phone: Fax: E-mail: The Pezcoller Foundation, in accordance with D. Lgs 30 June/2003 n. 196, declares that the data used in filling out this form will be used only for registration and internal information purposes. Our data processing is in conformity with the updated law. You may, at any time, exercise your rights in the presence of an electronic data processing titular (art. 7, D.Lgs 196/2003). I authorize the treatment of my personal data Signature Hotel reservations: Hotel: Date of arrival Date of departure..... Signature...... Date Important: Please pre-register by fax (0039)-0461-980350 or e-mail: pezcoller@pezcoller.it FONDAZIONE ALESSIO PEZCOLLER Via Dordi, 8 -38122 TRENTO (Italy) Phone 0039-0461-980250 Fax 0039-0461-980350 E-mail: pezcoller@pezcoller.it Web: www.pezcoller.it

Program Committee

David Livingston

Dana Farber Cancer Inst, Boston, MA

- Richard Marais

The Inst of Cancer Research London, UK

- Enrico Mihich

Dana Farber Cancer Inst, Boston, MA

William Sellers

Novartis Inst for Biomedical Res Cambridge, MA

The Pezcoller Foundation Symposia

24th Pezcoller Symposium

MOLECULAR BASIS FOR RESISTANCE TO TARGETED AGENTS

Trento, Italy, June 14-16, 2012 Conference Hall Fondazione Cassa di Risparmio di Trento e Rovereto, via Calepina 1 – 38122 Trento

Co-Chairmen and Program Committee Richard Marais, William Sellers, David Livingston and Enrico Mihich

The topic will be *Molecular Basis for Resistance to Targeted Agents*, and the focus of the meeting will be the mechanisms of resistance to new tumor target therapies.

The meeting is being co-organized by Richard Marais (Institute of Cancer Research, London, UK), William Sellers (Novartis Institute for Biomedical Research, Cambridge, MA), David Livingston (Dana Farber Cancer Institute, Boston, MA) and with the collaboration of Enrico Mihich (Dana Farber Cancer Institute, Boston, MA).

The Symposium will be opened by the keynote address of Jeffrey Engelman (MGH, Charlestown, MA).

There will be 22 speakers divided in five sessions: genetics of resistance I and II; clinical advance in overcoming resistance; resistance through perturbed signalling; role of the tumor microenvironment in resistance.

Speakers give approximately 25 minute talks followed by a similar amount of time for discussion. These meetings have always provided a major opportunity for scientific interaction among participants.

The Pezcoller Symposia